Clinical Cancer Research, Vol 4, Issue 1 145-152, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Selective sensitization to DNA-damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression

AA Gibson, FG Harwood, DM Tillman and JA Houghton
Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

Drug-induced cytotoxicity or apoptosis may be influenced by the expression of the p53 tumor suppressor gene and by the specific oncogene expressed, which may dictate the threshold at which a cytotoxic response may by induced. The objective of the study was to elucidate how DNA-damaging agents with different mechanisms of action were sensitized in the context of expression of the Pax3/FKHR fusion protein, a transformation event unique to alveolar rhabdomyosarcomas (ARMSs), and wild-type p53 (wtp53). A wtp53 cDNA was subcloned into the pGRE5-2/EBV vector with dexamethasone-inducible overexpression and transfected into Rh30 ARMS cells that express Pax3/FKHR and a mutant p53 phenotype. Following dexamethasone induction of wtp53 overexpression in a derived clone (Cl.#27), growth was slowed, and cells accumulated in G1. Functional wtp53 activity was demonstrated by selective transactivation of p50-2, a wtp53 chloramphenicol acetyltransferase reporter construct, and by up-regulated expression of endogenous p21Waf1. Data demonstrated p53-dependent sensitization (> or = 4-fold) to bleomycin, actinomycin D, and 5-fluorouracil and considerably less p53-dependence (< or = 2-fold) for doxorubicin, topotecan, etoposide, and cisplatin in Cl.#27 compared to an equivalent clone containing the pGRE5-EBV vector alone (VC#3). Data demonstrate that ARMS cells show a selective sensitization to DNA-damaging agents when wtp53 is overexpressed. The cytotoxic activity of agents that are not potentiated substantially must, therefore, depend upon p53-independent factors that relate to the mechanism of drug action.

This article has been cited by other articles:

				H Caldas, M P Holloway, B M Hall, S J Qualman, and R A Altura Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo J. Med. Genet., February 1, 2006; 43(2): 119 - 128. [Abstract] [Full Text] [PDF]

				F. Hassan, S. Islam, M. M. Mu, H. Ito, N. Koide, I. Mori, T. Yoshida, and T. Yokochi Lipopolysaccharide Prevents Doxorubicin-Induced Apoptosis in RAW 264.7 Macrophage Cells by Inhibiting p53 Activation Mol. Cancer Res., July 1, 2005; 3(7): 373 - 379. [Abstract] [Full Text] [PDF]

				P. P. McKenzie, C. R. McPake, A. A. Ashford, E. F. Vanin, and L. C. Harris MDM2 Does Not Influence p53-mediated Sensitivity to DNA-damaging Drugs Mol. Cancer Ther., October 1, 2002; 1(12): 1097 - 1104. [Abstract] [Full Text] [PDF]

				K. Kudoh, M. Takano, T. Koshikawa, M. Hirai, S. Yoshida, Y. Mano, K. Yamamoto, K. Ishii, T. Kita, Y. Kikuchi, et al. Gains of 1q21-q22 and 13q12-q14 Are Potential Indicators for Resistance to Cisplatin-based Chemotherapy in Ovarian Cancer Patients Clin. Cancer Res., September 1, 1999; 5(9): 2526 - 2531. [Abstract] [Full Text] [PDF]

				H. Hosoi, M. B. Dilling, T. Shikata, L. N. Liu, L. Shu, R. A. Ashmun, G. S. Germain, R. T. Abraham, and P. J. Houghton Rapamycin Causes Poorly Reversible Inhibition of mTOR and Induces p53-independent Apoptosis in Human Rhabdomyosarcoma Cells Cancer Res., February 1, 1999; 59(4): 886 - 894. [Abstract] [Full Text] [PDF]